Literature DB >> 22502868

Cardiovascular risk and atherosclerosis prevention.

Jiri Frohlich1, Ahmad Al-Sarraf.   

Abstract

Until recently, coronary artery disease (CAD) was the leading cause of death in the developed countries. Its remarkable decline can be attributed to our knowledge of the major risk factors identified by several studies resulting in better prevention and treatment. Of the major risk factors, the ratio of apolipoprotein (apo) B/apo A1 followed by smoking, diabetes, and hypertension are the most important. A number of risk scores for men and women are now available to estimate the likelihood of development of CAD. However, because of the risk of CAD differs in various populations, some of the algorithms are more appropriate for some countries but not suitable for others. These risk assessment algorithms differ in the parameters they use. All the risk scores have some limitations such as different study populations; the age of the study is also different, and number of points awarded for age categories also differs among the various algorithms. In an effort to further improve the risk prediction, a number of biomarkers have been studied. In addition to plasma lipids, a lot of interest has focused on apo measurements; particularly of apo B. Another valuable biomarker is lipoprotein (a) [Lp(a)]. Lp(a) is not only atherogenic as low-density lipoprotein (LDL) but also prothrombotic, and several studies indicate that Lp(a) is an independent risk factor for CAD. The lipid profile provides a framework for appropriate management. This includes therapeutic lifestyle changes and medications. Lifestyle interventions are the cornerstone of CAD prevention strategies and are the first step in risk factor management. Of particular importance are smoking cessation, achievement and maintenance of ideal body weight, regular exercise, reduction in the intake of saturated fat and sugars, and decreasing level of stress. Of medications, lipid-lowering, anti-hypertensive, and anti-coagulant can be effectively used. The current strategies for risk assessment and prevention have been very successful contributing to the more than 50% decrease in CAD mortality over the last 20 years. Thus, in Canada, cardiovascular disease is no longer the leading cause of death. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22502868     DOI: 10.1016/j.carpath.2012.03.001

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  15 in total

1.  High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice.

Authors:  Maarit Lehti; Elizabeth Donelan; William Abplanalp; Omar Al-Massadi; Kirk M Habegger; Jon Weber; Chandler Ress; Johannes Mansfeld; Sonal Somvanshi; Chitrang Trivedi; Michaela Keuper; Teja Ograjsek; Cynthia Striese; Sebastian Cucuruz; Paul T Pfluger; Radhakrishna Krishna; Scott M Gordon; R A Gangani D Silva; Serge Luquet; Julien Castel; Sarah Martinez; David D'Alessio; W Sean Davidson; Susanna M Hofmann
Journal:  Circulation       Date:  2013-10-29       Impact factor: 29.690

2.  Atherosclerosis associated with vasculopathic lesions in a golden retriever with hypercholesterolemia.

Authors:  Nicole A Boynosky; Laura Stokking
Journal:  Can Vet J       Date:  2014-05       Impact factor: 1.008

Review 3.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 4.  The pathobiology of acute coronary syndromes: clinical implications and central role of the mitochondria.

Authors:  L Maximilian Buja
Journal:  Tex Heart Inst J       Date:  2013

5.  Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis.

Authors:  Xiaowen Cheng; Xiaobian Wang; Yufeng Wan; Qing Zhou; Huaqing Zhu; Yuan Wang
Journal:  Mol Med Rep       Date:  2015-06-22       Impact factor: 2.952

6.  An association study between genetic polymorphism in the interleukin-6 receptor gene and coronary heart disease.

Authors:  Jiangqing Zhou; Xiaoliang Chen; Huadan Ye; Ping Peng; Yanna Ba; Xi Yang; Xiaoyan Huang; Yae Lu; Xin Jiang; Jiangfang Lian; Shiwei Duan
Journal:  Biomed Res Int       Date:  2014-05-26       Impact factor: 3.411

7.  Computed tomography imaging of early coronary artery lesions in stable individuals with multiple cardiovascular risk factors.

Authors:  Xi Yang; Hong Huang; Hong Liu; Zhi-Yu Zeng; Jie Zhang
Journal:  Clinics (Sao Paulo)       Date:  2015-04       Impact factor: 2.365

8.  Pathological interactions between the endothelin-1 and the angiotensin- converting enzyme among Tunisian coronary patients.

Authors:  Abdelkader Chalghoum; Yosri Noichri; Azza Dandana; Bruno Baudin; Abdelhédi Miled; Salima Ferchichi
Journal:  BMC Cardiovasc Disord       Date:  2016-11-29       Impact factor: 2.298

Review 9.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

10.  LncRNA SNHG12 regulates ox-LDL-induced endothelial cell injury by the miR-218-5p/IGF2 axis in atherosclerosis.

Authors:  Ping Mao; Xiaowei Liu; Yingzheng Wen; Lijiang Tang; Yimin Tang
Journal:  Cell Cycle       Date:  2021-07-27       Impact factor: 5.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.